This, in turn, resulted in a moderate reduction in Vegfa mRNA expression (Figure 14B), but was sufficient to inhibit the development of retinal NV at P17 (by almost 75%) in OIR mice (Figure 14C), which was similar to what was observed with aflibercept (Figure 14D) at a dose equivalent to what is being used for newborns with retinopathy of prematurity (ROP) (47). This evidence concerns the gene VEGFA and retinopathy of prematurity.